Results 101 to 110 of about 124,031 (252)

Efficacy of Inebilizumab in N‐MOmentum Trial Participants With or Without Prior Immunosuppressants

open access: yesAnnals of Clinical and Translational Neurology, EarlyView.
ABSTRACT This post hoc analysis examined the impact of prior immunosuppressants on the long‐term efficacy and safety of inebilizumab, a cluster of differentiation 19+ B‐cell–depleting monoclonal antibody, in participants with aquaporin‐4–seropositive neuromyelitis optica spectrum disorder from the N‐MOmentum trial (NTC02200770).
Bruce A. C. Cree   +9 more
wiley   +1 more source

Reliability Modeling Method for Constant Stress Accelerated Degradation Based on the Generalized Wiener Process

open access: yesEntropy
This paper aims to improve the accuracy of reliability estimates and the failure time prediction for products exhibiting nonlinear degradation behavior under constant-stress accelerated degradation test (CSADT). To achieve this, a novel degradation model
Shanshan Li, Zaizai Yan, Junmei Jia
doaj   +1 more source

Cognitive and Neuroimaging Divergence Between Juvenile and Adult FUS Amyotrophic Lateral Sclerosis

open access: yesAnnals of Clinical and Translational Neurology, EarlyView.
ABSTRACT Objective Amyotrophic lateral sclerosis (ALS) is a neurodegenerative disorder characterized by progressive motor neuron degeneration. Fused in sarcoma (FUS)‐associated juvenile ALS (jALS) represents a distinct and aggressive subgroup with rapid deterioration and poor prognosis.
Alexandra V. Jürs   +7 more
wiley   +1 more source

Prediction of time to reflux using accelerated failure time model of Weibull distribution in children with antenatal hydronephrosis

open access: yesJournal of Biostatistics and Epidemiology, 2018
Background & Aim: Prediction of time to reflux can aid healthcare providers and preparation programs. We constructed a risk prediction instrument for occurrence reflux in children with antenatal hydronephrosis.
Maryam Nazemipour   +3 more
doaj  

Deep Learning Pose Estimation for Phenotyping of Co‐Occurring Hyperkinetic Movement Disorders

open access: yesAnnals of Clinical and Translational Neurology, EarlyView.
ABSTRACT Objective To explore whether routine outpatient video combined with deep learning‐based pose estimation and clinically interpretable kinematic features can support multi‐label phenotyping of co‐occurring hyperkinetic movement disorders (HMDs).
Laura Cif   +17 more
wiley   +1 more source

Relationships between β-amyloid and tau in an elderly population: An accelerated failure time model. [PDF]

open access: yesNeuroimage, 2021
Therneau TM   +12 more
europepmc   +1 more source

Progressive Parkinsonism in PPP2R5D‐Related Neurodevelopmental Disorder

open access: yesAnnals of Clinical and Translational Neurology, EarlyView.
ABSTRACT PPP2R5D‐related neurodevelopmental disorder (Houge–Janssens syndrome type 1) is a rare autosomal dominant condition characterized by macrocephaly, intellectual disability, and epilepsy. Progressive parkinsonism is an emerging adult phenotype that neurologists should be aware of since timely genetic diagnosis opens the door to disease‐modifying
Katerina Bernardi   +6 more
wiley   +1 more source

Re‐Purposing Sapropterin (Kuvan) for ACTA2‐Related Multisystemic Smooth Muscle Dysfunction Syndrome: A Translational Mechanistic and First‐In‐Human Therapeutic Report

open access: yesAnnals of Clinical and Translational Neurology, EarlyView.
ABSTRACT Multisystemic smooth muscle dysfunction syndrome (MSMDS) is an ultra‐rare, ACTA2‐related disorder characterized by severe cerebrovascular disease, aortic aneurysms, and smooth muscle dysfunction. Using molecular dynamics simulations and in silico drug screening, we identified that sapropterin dihydrochloride (Kuvan) is a candidate capable of ...
Moran Hausman‐Kedem   +9 more
wiley   +1 more source

Time to recovery and determinant factors of COVID-19 patients under treatment in Sidama region, Ethiopia: A retrospective cohort study

open access: yesHeliyon
Introduction: Evidence from several studies shows that the median recovery time among COVID-19 patients varies in different settings, and why that difference occurs is questionable.
Samrawit Fantaw, Dereje Danbe Debeko
doaj   +1 more source

Home - About - Disclaimer - Privacy